SEATTLE and VANCOUVER, British Columbia, Sept. 5, 2019 /CNW/ -- Achieve Life
Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical
company committed to the global development and commercialization
of cytisinicline for smoking cessation, today announced the Company
will host its first investor day on Friday,
September 20, 2019 in New York City.
The event will include an updated data presentation by the
primary investigator of the Phase 2b
ORCA-1 trial of cytisinicline. It will also feature a panel
discussion moderated by leading healthcare analysts, Michael Higgins from Ladenburg Thalmann and
Jason McCarthy from Maxim Group,
with participation from four esteemed medical experts in the field
of smoking cessation.
In June of 2019, Achieve Life Sciences announced statistically
significant, topline results from its 254-subject, Phase
2b ORCA-1 dose-selection trial of
cytisinicline for smoking cessation. The outcome of the trial has
led to the selection of 3.0 mg, three times daily (TID) dosing for
future Phase 3 development. Cytisinicline treatment demonstrated
significant improvements across all treatment arms in both
reduction in cigarettes smoked and abstinence rates compared to
placebo. The most impressive results were observed in the 3 mg TID
treatment arm which demonstrated a 54% abstinence rate at week 4,
compared to 16% for placebo (p < 0.0001) and a continuous
abstinence rate, weeks 5 through 8, of 30% for cytisinicline
compared to 8% for placebo (p= 0.005). Four week continuous
abstinence is the relevant endpoint for regulatory approval.
The Investor Day will start at 12PM
ET and will be 2 hours in duration. This is an RSVP-only
event open to members of the investment community. Additional
details and registration information is available at the Achieve
website, http://ir.achievelifesciences.com/events-and-webcasts.
About Achieve Life Sciences
Tobacco use is currently
the leading cause of preventable death and is responsible for
nearly seven million deaths annually worldwide1. It is
estimated that 28.7% of cancer deaths in the U.S. are attributable
to cigarette smoking2.
Achieve's focus is to address the global smoking health epidemic
through the development and commercialization of cytisinicline.
Cytisinicline is a plant-based alkaloid with a high binding
affinity to the nicotinic acetylcholine receptor. It is believed to
aid in smoking cessation by interacting with nicotine receptors in
the brain by reducing the severity of nicotine withdrawal symptoms
and by reducing the reward and satisfaction associated with
smoking.
As an approved, branded product in Central and Eastern Europe for more than two decades, it
is estimated that over 20 million people have used cytisinicline to
help combat nicotine addiction.
Achieve Contact
Jason
Wong
jwong@bplifescience.com
(415) 375-3340 ext. 4
1 World Health Organization. WHO Report on
the Global Tobacco Epidemic, 2017. Geneva: World Health Organization, 2017
2 Annals of Epidemiology , Volume 25 , Issue 3 ,
179 - 182.e1
View original content to download
multimedia:http://www.prnewswire.com/news-releases/achieve-life-sciences-to-host-investor-day-on-september-20th-including-roundtable-discussion-with-smoking-cessation-medical-experts-and-final-data-from-the-phase-2b-orca-1-trial-300912096.html
SOURCE Achieve Life Sciences, Inc.